We Wu Biotech announced that the company recently obtained the “Notice of Acceptance” issued by the State Drug Administration, and the S01D drug clinical trial application has been officially accepted. The drug is registered as a chemical class 1 and is intended for the treatment of adult patients with drug-resistant tuberculosis. As of the date of disclosure of the announcement, the same chemical drug had not been approved for marketing at home or abroad.

We Wu Biotech announced that the company recently obtained the “Notice of Acceptance” issued by the State Drug Administration, and the S01D drug clinical trial application has been officially accepted. The drug is registered as a chemical class 1 and is intended for the treatment of adult patients with drug-resistant tuberculosis. As of the date of disclosure of the announcement, the same chemical drug had not been approved for marketing at home or abroad.